Top Luliconazole Cream Brands for Optimal Fungal Care

Luliconazole cream is a popular antifungal medication used to treat various skin infections effectively. With numerous brands available in the market, choosing the best one can often be overwhelming. The right brand often depends on factors such as formulation quality, price, and user reviews. To explore some of the top-recommended brands for Luliconazole cream, look below.

Illustration of luliconazole cream

Best brands of luliconazole cream in 2025

Luzu

Luzu, a brand name for luliconazole topical cream, is a highly effective treatment for interdigital tinea pedis, tinea cruris, and tinea corporis, approved by the FDA on November 14, 2013. It is indicated for patients 18 years of age and older, with a treatment duration of one to two weeks depending on the condition. Luliconazole cream has shown significant efficacy, with complete clearance rates significantly higher in treated groups compared to vehicle cream, such as 76.1% negative mycological results in the luliconazole group for tinea pedis. Developed and first marketed in Japan since 2005, Luzu has established itself as a reliable and potent azole antifungal product. There is currently no therapeutically equivalent generic version available in the United States. For more information on the usage and availability of Luzu, please visit the drugs.com availability page.

Lulicon

Luliconazole cream, marketed under the brand name Luzu, is a highly effective antifungal treatment produced by Medicis Pharmaceutical Corporation, now part of Valeant Pharmaceuticals. It has been shown to clear tinea pedis in as little as 2 weeks, with a mycological cure rate of 76.1% and clinical improvement in 91.5% of patients by the end of the treatment period. The cream is well-tolerated and has been approved for the treatment of tinea pedis, tinea cruris, and tinea corporis in patients 18 years or older. The maximum recommended dose is 8 grams per day for tinea corporis and 2 grams per day for tinea pedis, with no significant cardiovascular safety concerns noted in clinical studies. The global market for luliconazole cream is expected to grow significantly, reaching USD 10.02 billion by 2031. For more detailed information, you can refer to the FDA's documentation here.

Lulifin

Lulifin, a prominent brand, is renowned for its high-quality luliconazole cream, which is highly effective in treating fungal infections such as athlete's foot, jock itch, and ringworm. With a molecular formula of C14H9Cl2N3S2, luliconazole works by inhibiting the enzyme lanosterol demethylase, thereby preventing the synthesis of ergosterol, a crucial component of fungal cell membranes. The market for luliconazole cream is expected to grow significantly, reaching a valuation of USD 10.02 billion by 2031, driven by increasing demand and the expanding pharmaceutical sector. Lulifin cream is typically applied 1-2 times a day for 1-2 weeks, and it has a high protein binding rate of over 99%. The global market, particularly in the Asia-Pacific region, is seeing robust growth, with countries like China and India contributing significantly to the demand.

Lulibet

Lulibet, a product of Intas Pharmaceuticals Ltd, is a highly effective and reliable brand for luliconazole cream, known for its broad-spectrum antifungal properties. It is particularly effective in treating fungal skin infections such as athlete's foot, jock itch, and ringworm, achieving complete clearance of the infection and preventing recurrence. The cream contains 1% w/w luliconazole, which acts by inhibiting the synthesis of ergosterol, a crucial component of fungal cell membranes. With its well-tolerated profile and no serious adverse effects reported, Lulibet cream is a preferred therapy option. The market for luliconazole cream, including Lulibet, is expected to grow significantly, reaching a valuation of USD 10.02 billion by 2031. For more details, visit the official product page.

Luligee

Luligee, a renowned brand, stands out as a leading producer of luliconazole cream, known for its potent antifungal properties and high efficacy in treating skin fungal infections such as athlete's foot, jock itch, and ringworm. The market for luliconazole cream, including Luligee, is expected to grow from USD 5.85 billion in 2024 to USD 10.02 billion by 2031, driven by increasing demand and advancements in pharmaceutical formulations. Luligee's product is part of a market that has seen significant growth, with the global market projected to expand at a CAGR of around 8% during the forecast period. The brand's commitment to quality and effectiveness has made it a preferred choice among both patients and healthcare providers. With its strong presence in online and offline pharmacies, Luligee continues to contribute to the rising adoption of topical antifungal treatments. For more details, visit their Luligee Cream page.

Lulirx

Lulirx is a renowned brand for luliconazole cream, known for its efficacy in treating fungal skin infections such as athlete's foot, ringworm, and jock itch. The cream contains 1% luliconazole and is applied topically, showing strong fungicidal activity against dermatophytes like Trichophyton spp.

Luliz

Luzu, a brand of luliconazole cream, is renowned for its efficacy in treating fungal skin infections such as interdigital tinea pedis, tinea cruris, and tinea corporis, with a significant improvement rate of 91.5% in skin lesions by the fourth week of treatment. The cream, containing 1% luliconazole, has been shown to be well-tolerated, with most adverse reactions being mild and occurring in less than 1% of subjects. The market for luliconazole cream is expected to grow substantially, reaching a valuation of USD 10.02 billion by 2031, up from USD 5.85 billion in 2024. Luzu cream is applied once daily for 7 to 14 days, depending on the condition, and its systemic concentrations are quantifiable in all subjects, indicating effective absorption. The cream's popularity is driven by its potent antifungal properties and the increasing prevalence of fungal skin infections. For more information, visit the Luzu product page.

Lulinol

Luliconazole cream, particularly from brands like Luzu by Medicis Pharmaceutical Corporation, is highly regarded for its potent antifungal properties and efficacy in treating fungal skin infections such as interdigital tinea pedis, tinea cruris, and tinea corporis. It has been shown to clear infections in as little as two weeks, with significant clearance rates observed in clinical trials. For instance, in a study, luliconazole cream demonstrated complete clearance in a higher percentage of patients compared to vehicle cream, highlighting its effectiveness. The market for luliconazole cream is expected to grow substantially, reaching a valuation of USD 10.02 billion by 2031, driven by increasing demand and advancements in healthcare. This growth underscores the product's reliability and convenience as a topical antifungal treatment. For more detailed clinical information, you can refer to the FDA documentation on Luliconazole.

Luliderm

Luliderm, a product from Aristo Pharma, is a leading brand in the luliconazole cream market, known for its potent antifungal properties and efficacy in treating fungal skin infections such as athlete's foot and ringworm. The market for luliconazole cream is expected to grow to USD 5.85 Billion by 2024 and reach USD 10.02 Billion by 2031, driven by the increasing prevalence of fungal infections and rising awareness about effective antifungal treatments. Luliderm benefits from the robust growth of the pharmaceutical sector and improvements in healthcare access. The cream's popularity is also boosted by advancements in drug formulation and the preference for topical over systemic treatments. With a market share of 3.10%, Luliderm is a significant player in this expanding market.

Lulizol

Luliconazole cream, marketed under brands like Luzu, is a highly effective antifungal treatment produced by several leading pharmaceutical companies, including Medicis Pharmaceutical Corporation and others. This cream has shown significant efficacy in treating fungal skin infections such as athlete's foot, jock itch, and ringworm, with a market expected to grow from USD 5.85 Billion in 2024 to USD 10.02 Billion by 2031. The growth is driven by increasing prevalence of fungal infections and rising awareness about effective antifungal treatments. The product is available in various sizes, such as 15gm and 30gm, and is distributed through both online and offline pharmacies. Its potent antifungal properties and convenience have made it a preferred choice among patients and healthcare providers. For more detailed information, refer to the FDA documentation.